期刊
CURRENT VASCULAR PHARMACOLOGY
卷 10, 期 6, 页码 684-686出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/157016112803520864
关键词
Atherogenic dyslipidemia; VLDL secretion; apoB metabolism; insulin resistance
资金
- Progetto Ateneo University of Rome La Sapienze [C26A042949]
Diabetic dyslipidemia is due to a multiple array of metabolic abnormalities determining a typical phenotype characterized by increased plasma triglycerides, reduced HDL and a preponderance of small, dense LDL. This dyslipidemia, defined as atherogenic dyslipidemia, is thought to be highly responsible for the increased cardiovascular risk in diabetes mellitus. Several lines of evidence indicate that the increased liver production of VLDL is the main underlying defect in atherogenic dyslipidemia. This review will recapitulate the pathophysiological aspects of diabetic dyslipidemia with special focus on the molecular mechanism causing increased liver production of VLDL in diabetic patients. The consequences of atherogenic dyslipidemia on mechanisms of atherogenesis will be also reviewed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据